Get the Stockscreener App
1.46
5.80%
0.08
After Hours:
1.46
Cognition Therapeutics Inc stock is traded at $1.46, with a volume of 1.25M.
It is up +5.80% in the last 24 hours and down -3.95% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
See More
Previous Close:
$1.38
Open:
$1.37
24h Volume:
1.25M
Relative Volume:
1.22
Market Cap:
$128.88M
Revenue:
-
Net Income/Loss:
$-22.83M
P/E Ratio:
-1.8481
EPS:
-0.79
Net Cash Flow:
$-20.87M
1W Performance:
+3.55%
1M Performance:
-3.95%
6M Performance:
+136.78%
1Y Performance:
+110.28%
1-Day Range:
$1.37
$1.51
1-Week Range:
$1.37
$1.51
52-Week Range:
$0.2223
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.46 | 121.82M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
Market Catalysts: What is Cognition Therapeutics Incs debt to equity ratioInsider Selling & Capital Protection Trading Alerts - baoquankhu1.vn
Aug Catalysts: Whats the fair value of Cognition Therapeutics Inc stockPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
Whats the fair value of Cognition Therapeutics Inc stock2025 Price Targets & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
CEO Moves: Is Cognition Therapeutics Inc stock a top pick in earnings season2025 Risk Factors & Precise Trade Entry Recommendations - Bộ Nội Vụ
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Cognition Therapeutics Inc. stock could outperform in 2025Earnings Recap Report & High Yield Equity Trading Tips - Улправда
Trading Recap: Will Cognition Therapeutics Inc. stock outperform growth indexes2025 Analyst Calls & Community Consensus Trade Alerts - Улправда
How resilient is Cognition Therapeutics Inc. stock in market downturnsJuly 2025 Trade Ideas & Long-Term Investment Growth Plans - Улправда
Weekly Earnings: How Cognition Therapeutics Inc. stock reacts to oil pricesEarnings Performance Report & Stepwise Trade Signal Implementation - Улправда
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - FinancialContent
Cognition Therapeutics Announces Publication of Phase 2 Study Results for Zervimesine in Dementia with Lewy Bodies - Quiver Quantitative
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX - MarketBeat
Earnings Risk: Why Cognition Therapeutics Inc stock could outperform in 2025Earnings Summary Report & Community Consensus Stock Picks - moha.gov.vn
How Cognition Therapeutics Inc. stock reacts to oil prices2025 Earnings Impact & Daily Technical Stock Forecast Reports - Улправда
[8-K] COGNITION THERAPEUTICS INC Reports Material Event | CGTX SEC FilingForm 8-K - Stock Titan
Cognition Therapeutics Launches New $75M ATM Offering - TipRanks
Growth Value: How Cognition Therapeutics Inc. stock reacts to oil prices2025 Short Interest & Daily Profit Maximizing Tips - Улправда
[S-3] COGNITION THERAPEUTICS INC Shelf Registration Statement | CGTX SEC FilingForm S-3 - Stock Titan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Why retail investors pile into Cognition Therapeutics Inc. stock2025 Growth vs Value & Daily Momentum Trading Reports - Newser
HC Wainwright & Co. Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
CGTX Analyst Rating: HC Wainwright & Co. Maintains Buy Rating | - GuruFocus
Why Cognition Therapeutics Inc. stock is favored by pension fundsJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - Newser
Cognition Therapeutics completes enrollment in expanded access program By Investing.com - Investing.com Nigeria
Cognition Therapeutics completes enrollment in expanded access program - Investing.com India
Cognition Therapeutics Says Zervimesine Expanded Access Program Reaches Full Enrollment - marketscreener.com
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - Yahoo Finance
Cognition Therapeutics (CGTX) Stock Analysis Report | Financials & Insights - Benzinga
Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s - MSN
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug By Investing.com - Investing.com Nigeria
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug - Investing.com
Cognition Therapeutics outlines phase 3 Alzheimer's plan at CTAD - marketscreener.com
Cognition Therapeutics Outlines Phase 3 Alzheimer's Plan at CTAD - TradingView
Cognition Therapeutics, Inc. Plans to Align with EMA on Alzheimer's Disease Strategy for Zervimesine at February 2026 Meeting - Quiver Quantitative
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - Stock Titan
Cognition Therapeutics Inc Stock Analysis and ForecastConsumer Goods Stocks & Affordable Market Investment - earlytimes.in
Cognition Therapeutics Inc. (CGTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Q1 Earnings Forecast for CGTX Issued By B. Riley - MarketBeat
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cognition Therapeutics: A High-Stakes Bet On A Single DrugWhy I Hold (NASDAQ:CGTX) - Seeking Alpha
B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq
Cognition Therapeutics (CGTX) Sees Analyst Price Target Boost | CGTX Stock News - GuruFocus
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating - marketscreener.com
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference - The Manila Times
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Speak at Annual Piper Sandler Healthcare Conference - Quiver Quantitative
Cognition Therapeutics (Nasdaq: CGTX) CEO Talk at 37th Piper Sandler Healthcare Conf - Stock Titan
Will Cognition Therapeutics Inc. stock beat EPS estimatesJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cognition Therapeutics Inc Stock (CGTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ricciardi Lisa | CEO & President |
Jan 31 '25 |
Buy |
0.77 |
38,851 |
30,001 |
38,851 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):